Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MesoPher,Mitazalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MesoPher (Autologous Tumor Lysate-Loaded Dendritic Cell) is comprised of autologous patient DCs loaded with “PheraLys” – Amphera’s allogeneic lysate of mesothelioma cell lines and being developed for pancreatic cancer.
Product Name : MesoPher
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : MesoPher,Mitazalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MesoPher
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amphera Announces Clinical Updates of MesoPher Cell Therapy
Details : The DENIM trial confirmed MesoPher’s excellent safety profile and MesoPher induced a robust T-cell response. The immune response did not translate into clinical benefit, and consequently the primary endpoint of an improvement of Overall Survival (OS) w...
Product Name : MesoPher
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : MesoPher
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The latest REACtiVe data for MesoPher showed an average Overall Survival after surgery of approximately 36 months, with 8 of 10 patients alive, which is far beyond expected survival.
Product Name : MesoPher
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : MesoPher
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients received 3 bi-weekly injections of MesoPher, plus two further injections of MesoPher after 4 and 7 months. Patients in the control arm received best supportive care alone. The primary endpoint of the study is overall survival.
Product Name : MesoPher
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : MesoPher
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable